It’s hardly a secret that Dexcom and Abbott are dominating the CGM market. Both companies have held steady with their respective strategies. Dexcom is considered the premium system while Abbott has positioned Libre as the value offering. At the moment Dexcom has one major advantage over Libre as so far none of the Libre systems have been approved to be used with automated insulin delivery (AID) systems.
Well according to sources inside of Abbott the company may have another much more serious problem on their hands. These sources have told Diabetic Investor that the FDA is looking into . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.